|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: PLEKHA7 |
Gene summary for PLEKHA7 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | PLEKHA7 | Gene ID | 144100 |
| Gene name | pleckstrin homology domain containing A7 | |
| Gene Alias | PLEKHA7 | |
| Cytomap | 11p15.2-p15.1 | |
| Gene Type | protein-coding | GO ID | GO:0007155 | UniProtAcc | E9PKC0 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 144100 | PLEKHA7 | CCI_1 | Human | Cervix | CC | 8.91e-08 | 8.56e-01 | 0.528 |
| 144100 | PLEKHA7 | CCI_2 | Human | Cervix | CC | 4.11e-32 | 1.68e+00 | 0.5249 |
| 144100 | PLEKHA7 | CCI_3 | Human | Cervix | CC | 1.08e-12 | 9.58e-01 | 0.516 |
| 144100 | PLEKHA7 | CCII_1 | Human | Cervix | CC | 3.48e-04 | 2.90e-01 | 0.3249 |
| 144100 | PLEKHA7 | HTA11_2487_2000001011 | Human | Colorectum | SER | 2.78e-14 | 9.11e-01 | -0.1808 |
| 144100 | PLEKHA7 | HTA11_2951_2000001011 | Human | Colorectum | AD | 6.51e-11 | 9.95e-01 | 0.0216 |
| 144100 | PLEKHA7 | HTA11_1938_2000001011 | Human | Colorectum | AD | 1.27e-14 | 8.90e-01 | -0.0811 |
| 144100 | PLEKHA7 | HTA11_347_2000001011 | Human | Colorectum | AD | 1.58e-33 | 1.10e+00 | -0.1954 |
| 144100 | PLEKHA7 | HTA11_411_2000001011 | Human | Colorectum | SER | 1.05e-17 | 1.62e+00 | -0.2602 |
| 144100 | PLEKHA7 | HTA11_2112_2000001011 | Human | Colorectum | SER | 1.29e-15 | 1.43e+00 | -0.2196 |
| 144100 | PLEKHA7 | HTA11_3361_2000001011 | Human | Colorectum | AD | 1.04e-13 | 8.71e-01 | -0.1207 |
| 144100 | PLEKHA7 | HTA11_83_2000001011 | Human | Colorectum | SER | 1.53e-21 | 1.20e+00 | -0.1526 |
| 144100 | PLEKHA7 | HTA11_696_2000001011 | Human | Colorectum | AD | 3.83e-34 | 1.23e+00 | -0.1464 |
| 144100 | PLEKHA7 | HTA11_866_2000001011 | Human | Colorectum | AD | 3.12e-27 | 1.09e+00 | -0.1001 |
| 144100 | PLEKHA7 | HTA11_1391_2000001011 | Human | Colorectum | AD | 9.34e-20 | 1.24e+00 | -0.059 |
| 144100 | PLEKHA7 | HTA11_2992_2000001011 | Human | Colorectum | SER | 7.77e-08 | 9.84e-01 | -0.1706 |
| 144100 | PLEKHA7 | HTA11_5216_2000001011 | Human | Colorectum | SER | 3.45e-08 | 8.92e-01 | -0.1462 |
| 144100 | PLEKHA7 | HTA11_546_2000001011 | Human | Colorectum | AD | 1.11e-13 | 9.30e-01 | -0.0842 |
| 144100 | PLEKHA7 | HTA11_9341_2000001011 | Human | Colorectum | SER | 1.61e-08 | 1.01e+00 | -0.00410000000000005 |
| 144100 | PLEKHA7 | HTA11_7862_2000001011 | Human | Colorectum | AD | 1.66e-03 | 5.70e-01 | -0.0179 |
| Page: 1 2 3 4 5 6 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Cervix |  | CC: Cervix cancer |
| HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions | ||
| N_HPV: HPV-infected normal cervix | ||
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Endometrium |  | AEH: Atypical endometrial hyperplasia |
| EEC: Endometrioid Cancer | ||
| GC |  | CAG: Chronic atrophic gastritis |
| CAG with IM: Chronic atrophic gastritis with intestinal metaplasia | ||
| CSG: Chronic superficial gastritis | ||
| GC: Gastric cancer | ||
| SIM: Severe intestinal metaplasia | ||
| WIM: Wild intestinal metaplasia | ||
| Lung |  | AAH: Atypical adenomatous hyperplasia |
| AIS: Adenocarcinoma in situ | ||
| IAC: Invasive lung adenocarcinoma | ||
| MIA: Minimally invasive adenocarcinoma |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00452169 | Cervix | CC | cell-cell junction organization | 53/2311 | 200/18723 | 3.83e-08 | 2.53e-06 | 53 |
| GO:00469312 | Cervix | CC | pore complex assembly | 9/2311 | 20/18723 | 3.06e-04 | 3.27e-03 | 9 |
| GO:0044331 | Cervix | CC | cell-cell adhesion mediated by cadherin | 9/2311 | 28/18723 | 5.02e-03 | 2.98e-02 | 9 |
| GO:00343326 | Cervix | CC | adherens junction organization | 13/2311 | 49/18723 | 5.34e-03 | 3.10e-02 | 13 |
| GO:00343316 | Cervix | CC | cell junction maintenance | 10/2311 | 35/18723 | 7.99e-03 | 4.18e-02 | 10 |
| GO:0045216 | Colorectum | AD | cell-cell junction organization | 80/3918 | 200/18723 | 5.57e-10 | 4.58e-08 | 80 |
| GO:0043954 | Colorectum | AD | cellular component maintenance | 26/3918 | 61/18723 | 1.04e-04 | 1.56e-03 | 26 |
| GO:0034332 | Colorectum | AD | adherens junction organization | 20/3918 | 49/18723 | 1.23e-03 | 1.09e-02 | 20 |
| GO:0034331 | Colorectum | AD | cell junction maintenance | 15/3918 | 35/18723 | 2.78e-03 | 2.09e-02 | 15 |
| GO:00452161 | Colorectum | SER | cell-cell junction organization | 63/2897 | 200/18723 | 9.15e-09 | 7.80e-07 | 63 |
| GO:00439541 | Colorectum | SER | cellular component maintenance | 22/2897 | 61/18723 | 6.47e-05 | 1.49e-03 | 22 |
| GO:00343311 | Colorectum | SER | cell junction maintenance | 12/2897 | 35/18723 | 4.72e-03 | 3.71e-02 | 12 |
| GO:00452162 | Colorectum | MSS | cell-cell junction organization | 69/3467 | 200/18723 | 5.07e-08 | 2.70e-06 | 69 |
| GO:00439542 | Colorectum | MSS | cellular component maintenance | 22/3467 | 61/18723 | 9.05e-04 | 9.21e-03 | 22 |
| GO:00343321 | Colorectum | MSS | adherens junction organization | 18/3467 | 49/18723 | 2.03e-03 | 1.74e-02 | 18 |
| GO:00343312 | Colorectum | MSS | cell junction maintenance | 13/3467 | 35/18723 | 7.38e-03 | 4.68e-02 | 13 |
| GO:00452163 | Colorectum | MSI-H | cell-cell junction organization | 28/1319 | 200/18723 | 3.82e-04 | 8.73e-03 | 28 |
| GO:00452164 | Colorectum | FAP | cell-cell junction organization | 58/2622 | 200/18723 | 2.51e-08 | 2.36e-06 | 58 |
| GO:00343322 | Colorectum | FAP | adherens junction organization | 18/2622 | 49/18723 | 6.06e-05 | 1.19e-03 | 18 |
| GO:00439543 | Colorectum | FAP | cellular component maintenance | 19/2622 | 61/18723 | 4.61e-04 | 5.39e-03 | 19 |
| Page: 1 2 3 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| PLEKHA7 | SNV | Missense_Mutation | rs146138261 | c.611N>T | p.Ala204Val | p.A204V | Q6IQ23 | protein_coding | tolerated(0.14) | benign(0.005) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| PLEKHA7 | SNV | Missense_Mutation | novel | c.1871N>T | p.Ser624Leu | p.S624L | Q6IQ23 | protein_coding | tolerated(0.06) | benign(0.323) | TCGA-AR-A2LE-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | tamoxiphen | PD |
| PLEKHA7 | insertion | In_Frame_Ins | novel | c.1781_1782insGACTTCTTGTCTCCCCACTTGCAGAACTCATCTCATGTGGAC | p.Thr595_Val596insSerCysLeuProThrCysArgThrHisLeuMetTrpThrThr | p.T595_V596insSCLPTCRTHLMWTT | Q6IQ23 | protein_coding | TCGA-A8-A0A4-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | tamoxiphen | CR | ||
| PLEKHA7 | insertion | Frame_Shift_Ins | novel | c.964_965insAGGCCAGAGTTCAGTCCTGGGTCTGTGAGCCTCCAAGGCCTCCATGC | p.Arg322LysfsTer200 | p.R322Kfs*200 | Q6IQ23 | protein_coding | TCGA-B6-A0RE-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | ||
| PLEKHA7 | deletion | Frame_Shift_Del | novel | c.466delN | p.Ala156ProfsTer12 | p.A156Pfs*12 | Q6IQ23 | protein_coding | TCGA-D8-A27V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD | ||
| PLEKHA7 | SNV | Missense_Mutation | novel | c.3056N>C | p.Leu1019Pro | p.L1019P | Q6IQ23 | protein_coding | tolerated(0.18) | possibly_damaging(0.87) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| PLEKHA7 | SNV | Missense_Mutation | rs200470818 | c.892N>T | p.Arg298Trp | p.R298W | Q6IQ23 | protein_coding | tolerated(0.08) | benign(0) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| PLEKHA7 | SNV | Missense_Mutation | novel | c.2263G>A | p.Glu755Lys | p.E755K | Q6IQ23 | protein_coding | deleterious(0.01) | probably_damaging(0.98) | TCGA-VS-A9UC-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | SD |
| PLEKHA7 | SNV | Missense_Mutation | novel | c.2860N>T | p.Arg954Trp | p.R954W | Q6IQ23 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-5M-AAT6-01 | Colorectum | colon adenocarcinoma | Female | <65 | III/IV | Unknown | Unknown | PD |
| PLEKHA7 | SNV | Missense_Mutation | novel | c.2858N>G | p.Val953Gly | p.V953G | Q6IQ23 | protein_coding | deleterious(0) | probably_damaging(0.996) | TCGA-A6-6653-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |